SCHEMBL5875902

SCHEMBL5875902

CC(C=Cc1ccccc1)=C(C)C(=O)O.COC(=O)C(C)=CC=Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
ALDH1A1 P00352 3/20 0.46
GLA P06280 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 2/20 0.43
POLB P06746 1/20 0.41
HDAC3 O15379 3/20 0.40
HDAC4 P56524 3/20 0.40
HDAC1 Q13547 3/20 0.40
HDAC2 Q92769 3/20 0.40
HDAC8 Q9BY41 3/20 0.40
HDAC6 Q9UBN7 3/20 0.40
CYP2C9 P11712 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40
HDAC5 Q9UQL6 2/20 0.40
CYP1A2 P05177 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8991908 0.87 LMNA (0.60) LMNAALDH1A1GLATDP1KDM4E
SCHEMBL35777 0.87 LMNA (0.60) LMNAALDH1A1GLATDP1KDM4E
SCHEMBL1172155 0.83 LMNA (0.53) LMNAALDH1A1GLATDP1KDM4E
SCHEMBL10623293 0.82 LMNA (0.54) LMNAALDH1A1GLATDP1KDM4E
SCHEMBL10623290 0.82 LMNA (0.54) LMNAALDH1A1GLATDP1KDM4E
SCHEMBL8037377 0.81 GLA (0.56) LMNAALDH1A1GLATDP1HDAC3
SCHEMBL221211 0.81 TDP1 (0.64) LMNAALDH1A1GLATDP1HDAC3
SCHEMBL3127156 0.81 TDP1 (0.64) LMNAALDH1A1GLATDP1HDAC3
SCHEMBL4535017 0.78 LMNA (0.48) LMNAALDH1A1GLATDP1KDM4E
SCHEMBL2032564 0.77 LMNA (0.52) LMNAALDH1A1GLATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6815498-B2 BLOCK POLYMERS BASF AKTIENGESELLSCHAFT (DE) 2004-11-09 US claimed
EP-1252203-B1 METHOD FOR PRODUCING A POLYMERIC CONVERSION PRODUCT BASF AG (DE) 2004-03-17 EP claimed
US-20030018137-A1 Method for producing a polymeric conversion product BASF AKTIENGESELLSCHAFT (DE) 2003-01-23 US claimed
US-7008990-B2 Use of polymeric reaction product BASF AKTIENGESELLSCHAFT (DE) 2006-03-07 US disclosed
US-6815498-B2 BLOCK POLYMERS BASF AKTIENGESELLSCHAFT (DE) 2004-11-09 US disclosed
US-20040034182-A1 Method for the production of a polymerisation reaction product BASF AKTIENGESELLSCHAFT (DE) 2004-02-19 US disclosed
US-20040014872-A1 Bonding agent composition containing solid matter, with radically polymerised block copolymers BASF AKTIENGESELLSCHAFT (DE) 2004-01-22 US disclosed
US-20030170306-A1 Use of polymeric reaction product BASF AKTIENGESELLSCHAFT (DE) 2003-09-11 US disclosed
US-20030018137-A1 Method for producing a polymeric conversion product BASF AKTIENGESELLSCHAFT (DE) 2003-01-23 US disclosed
US-6506836-B1 Reacting under free-radical conditions a reaction mixture comprising at least one free-radically reactable monomer (a) in the presence of at least one free-radical initiator and of a compound process for preparing a polymer using said reaction BASF AKTIENGESELLSCHAFT (DE) 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030170306-A1 Use of polymeric reaction product OXSR1, OGFR, CBR1 LMNA 1810/4885ALDH1A1 2250/4885GLA 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.